An Open-Label Drug Interaction Study to Assess the Pharmacokinetics of JNJ-42847922 When Administered Alone and in Combination With Rifampin in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 10 May 2016
At a glance
- Drugs Seltorexant (Primary) ; Rifampicin
- Indications Insomnia; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 04 May 2016 Status changed from recruiting to completed.
- 18 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 04 Feb 2016 New trial record